Aristotle Fund LP Upped Mckesson Corp. (MCK) Holding; Ironwood Pharmaceuticals (IRWD) Valuation Rose While Private Wealth Partners Has Decreased Position by $573,000

February 20, 2018 - By Marie Mckinney

Aristotle Fund Lp increased its stake in Mckesson Corp. (MCK) by 20.46% based on its latest 2017Q3 regulatory filing with the SEC. Aristotle Fund Lp bought 28,200 shares as the company’s stock rose 1.84% with the market. The hedge fund held 166,000 shares of the other pharmaceuticals company at the end of 2017Q3, valued at $25.50M, up from 137,800 at the end of the previous reported quarter. Aristotle Fund Lp who had been investing in Mckesson Corp. for a number of months, seems to be bullish on the $30.81 billion market cap company. The stock decreased 0.78% or $1.17 during the last trading session, reaching $149.33. About 339,225 shares traded. McKesson Corporation (NYSE:MCK) has declined 15.45% since February 20, 2017 and is downtrending. It has underperformed by 32.15% the S&P500.




Private Wealth Partners Llc decreased its stake in Ironwood Pharmaceuticals Inc (IRWD) by 77.05% based on its latest 2017Q3 regulatory filing with the SEC. Private Wealth Partners Llc sold 38,200 shares as the company’s stock rose 3.03% with the market. The institutional investor held 11,380 shares of the health care company at the end of 2017Q3, valued at $179,000, down from 49,580 at the end of the previous reported quarter. Private Wealth Partners Llc who had been investing in Ironwood Pharmaceuticals Inc for a number of months, seems to be less bullish one the $2.25B market cap company. The stock decreased 2.28% or $0.35 during the last trading session, reaching $15.01. About 272,923 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has risen 57.40% since February 20, 2017 and is uptrending. It has outperformed by 40.70% the S&P500.

Investors sentiment decreased to 0.88 in Q3 2017. Its down 0.07, from 0.95 in 2017Q2. It dropped, as 65 investors sold MCK shares while 296 reduced holdings. 72 funds opened positions while 246 raised stakes. 180.04 million shares or 2.23% more from 176.11 million shares in 2017Q2 were reported. Pitcairn accumulated 4,344 shares or 0.08% of the stock. Afam Cap Incorporated reported 0.42% stake. Sequoia Financial Ltd Liability Com holds 0.04% in McKesson Corporation (NYSE:MCK) or 1,931 shares. Meyer Handelman Com reported 1.22% stake. Cullinan Assocs Inc reported 4,340 shares. Goelzer Investment Mgmt owns 8,100 shares for 0.15% of their portfolio. Van Eck owns 301,524 shares for 0.24% of their portfolio. Tdam Usa holds 0.55% or 60,724 shares. Altavista Wealth Mgmt, North Carolina-based fund reported 18,348 shares. Insur Tx owns 14,370 shares or 0.12% of their US portfolio. Lowe Brockenbrough And Inc accumulated 30,156 shares. Pictet Asset Limited accumulated 113,808 shares or 0.05% of the stock. 149,840 are held by Pnc Fincl Services Group. Cap One National Association owns 7,302 shares or 0.08% of their US portfolio. Brinker accumulated 9,990 shares or 0.06% of the stock.

Among 22 analysts covering McKesson Corporation (NYSE:MCK), 12 have Buy rating, 1 Sell and 9 Hold. Therefore 55% are positive. McKesson Corporation had 79 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was upgraded by Jefferies to “Buy” on Friday, July 28. JP Morgan downgraded the stock to “Neutral” rating in Thursday, January 5 report. Mizuho maintained McKesson Corporation (NYSE:MCK) on Monday, September 26 with “Neutral” rating. The firm earned “Hold” rating on Friday, November 11 by Standpoint Research. The firm has “Buy” rating by Needham given on Monday, October 16. The firm has “Buy” rating by Needham given on Friday, February 2. The stock has “Hold” rating by Mizuho on Tuesday, October 24. The stock of McKesson Corporation (NYSE:MCK) earned “Buy” rating by Needham on Wednesday, November 1. The stock has “Neutral” rating by Mizuho on Thursday, August 11. Goldman Sachs downgraded the shares of MCK in report on Wednesday, November 4 to “Buy” rating.

Since August 21, 2017, it had 0 insider buys, and 5 sales for $121.68 million activity. Lampert Erin M sold $140,089 worth of McKesson Corporation (NYSE:MCK) on Thursday, September 7. 1,083 McKesson Corporation (NYSE:MCK) shares with value of $157,500 were sold by JACOBS M CHRISTINE.

Investors sentiment decreased to 1.25 in 2017 Q3. Its down 0.06, from 1.31 in 2017Q2. It fall, as 24 investors sold IRWD shares while 32 reduced holdings. 13 funds opened positions while 57 raised stakes. 154.60 million shares or 6.92% more from 144.60 million shares in 2017Q2 were reported. Washington-based Parametric Portfolio Associate Ltd Limited Liability Company has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). D E Shaw Company stated it has 291,857 shares. 107,367 are held by Paloma Ptnrs Management. The Illinois-based First Advisors LP has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Prudential Fin owns 14,564 shares. 55,869 were reported by Cornerstone Capital Limited Liability. Adage Partners Group Incorporated Llc holds 2.90 million shares or 0.11% of its portfolio. Amer Intll Grp Incorporated Inc invested in 90,291 shares or 0.01% of the stock. Swiss Commercial Bank accumulated 0% or 210,500 shares. The United Kingdom-based Pictet Asset Mgmt Ltd has invested 0.12% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Metropolitan Life Ins Company stated it has 91,282 shares. Legal General Gp Public Ltd owns 0% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 55,707 shares. 94,216 were accumulated by Parallax Volatility Advisers L P. Next Fincl Group Inc accumulated 100 shares. Citigroup holds 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 133,928 shares.

Private Wealth Partners Llc, which manages about $794.14M and $497.39 million US Long portfolio, upped its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 4,824 shares to 90,383 shares, valued at $17.10M in 2017Q3, according to the filing. It also increased its holding in Hasbro Inc (NASDAQ:HAS) by 47,476 shares in the quarter, for a total of 51,057 shares, and has risen its stake in Priceline Grp Inc (NASDAQ:PCLN).

Among 15 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 4 have Buy rating, 2 Sell and 9 Hold. Therefore 27% are positive. Ironwood Pharmaceuticals had 37 analyst reports since August 6, 2015 according to SRatingsIntel. Mizuho maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Tuesday, January 9 with “Hold” rating. Mizuho downgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Wednesday, December 6 to “Neutral” rating. The rating was maintained by Wedbush on Monday, October 24 with “Neutral”. Cowen & Co upgraded Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Wednesday, April 6 to “Outperform” rating. The company was maintained on Friday, November 4 by Mizuho. The company was downgraded on Monday, August 10 by Zacks. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has “Buy” rating given on Monday, August 21 by Cowen & Co. Wedbush maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Thursday, April 28. Wedbush has “Neutral” rating and $10 target. The stock of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) earned “Buy” rating by Mizuho on Tuesday, May 10. The firm has “Hold” rating given on Tuesday, September 27 by WallachBeth Capital.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.